Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q2 2023 vs. Q1 2023
How the institutions holding Damora Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 26 | 27 | +1 |
| Shares | 8.96M | 10.2M | +1.23M (+13.8%) |
| Value | $17.8M | $25.7M | +$7.86M (+44.0%) |
New holders (3)
Institutions that held Damora Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Soleus Capital Management, L.P. | 1,000,000 | $2.52M | 0.28% |
| Charles Schwab Investment Management Inc | 15,761 | $39.7K | 0.00% |
| Belvedere Trading LLC | 15,037 | $37.9K | 0.01% |
Sold out (2)
Institutions that held Damora Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| UBS Group AG | 2,484 | $4.94K |
| Northwestern Mutual Wealth Management Co | 1,400 | $2.79K |